Why the study?
Does valsartan reduce atrial fibrillation recurrence in patients with a history of recent atrial fibrillation and underlying cardiovascular diseases?
Population
1402 patients with symptomatic atrial fibrillation with underlying cardiovascular diseases or comorbidities
Comparison
Valsartan added to best recommended therapies vs Placebo added to best recommended therapies
Design
RCT, 1:1 ratio, placebo-controlled
Follow-up
12 months
Authors
Loading...
RCT tests valsartan for AF recurrence prevention in CVD patients; provides Level 2 evidence on ARB role.
Does valsartan reduce atrial fibrillation recurrence in patients with a history of recent atrial fibrillation and underlying cardiovascular diseases?
The GISSI-AF trial is designed to evaluate whether the addition of valsartan to standard therapy reduces the recurrence of atrial fibrillation in patients with a recent history of AF and underlying cardiovascular disease.
Disertori et al. (2006) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: